awmsg logo



fondaparinux (Arixtra®)


Reference No. 149

Publication date:
22/05/2008


Appraisal information

fondaparinux (Arixtra®) solution for injection


Company: GlaxoSmithKline
BNF category: Cardiovascular system
NMG meeting date: 13/03/2008
AWMSG meeting date: 16/04/2008
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0508
Ministerial ratification: 20/05/2008

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Fondaparinux (Arixtra®) should be recommended as an option for use in the treatment of ST segment elevation myocardial infarction (STEMI) in patients who are managed with thrombolytics or who are initially to receive no other form of reperfusion therapy. Treatment with fondaparinux (Arixtra®) and its monitoring/supervision should be retained under secondary care. AWMSG is of the opinion that fondaparinux (Arixtra®) would not be suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download